PE75299A1 - Formulacion inyectable transparente de compuesto anestesico - Google Patents

Formulacion inyectable transparente de compuesto anestesico

Info

Publication number
PE75299A1
PE75299A1 PE1998000393A PE00039398A PE75299A1 PE 75299 A1 PE75299 A1 PE 75299A1 PE 1998000393 A PE1998000393 A PE 1998000393A PE 00039398 A PE00039398 A PE 00039398A PE 75299 A1 PE75299 A1 PE 75299A1
Authority
PE
Peru
Prior art keywords
solution
lecithin
injectable formulation
propofol
preference
Prior art date
Application number
PE1998000393A
Other languages
English (en)
Spanish (es)
Inventor
Tommaso Vincenzo De
Original Assignee
Saucy Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Saucy Ltd filed Critical Saucy Ltd
Publication of PE75299A1 publication Critical patent/PE75299A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PE1998000393A 1997-05-26 1998-05-19 Formulacion inyectable transparente de compuesto anestesico PE75299A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH01224/97A CH692322A5 (it) 1997-05-26 1997-05-26 Formulazione iniettabile limpida di Propofol.

Publications (1)

Publication Number Publication Date
PE75299A1 true PE75299A1 (es) 1999-08-26

Family

ID=4205400

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000393A PE75299A1 (es) 1997-05-26 1998-05-19 Formulacion inyectable transparente de compuesto anestesico

Country Status (23)

Country Link
US (1) US6326406B1 (enExample)
EP (1) EP0991405B1 (enExample)
JP (1) JP2001527577A (enExample)
KR (1) KR20010013011A (enExample)
CN (1) CN1268051A (enExample)
AR (1) AR012853A1 (enExample)
AT (1) ATE230984T1 (enExample)
AU (1) AU735020B2 (enExample)
BR (1) BR9809492A (enExample)
CA (1) CA2291261A1 (enExample)
CH (1) CH692322A5 (enExample)
DE (1) DE69810771D1 (enExample)
DZ (1) DZ2503A1 (enExample)
HU (1) HUP0002117A3 (enExample)
IN (1) IN187550B (enExample)
MY (1) MY132911A (enExample)
NO (1) NO995831L (enExample)
PA (1) PA8451701A1 (enExample)
PE (1) PE75299A1 (enExample)
PL (1) PL337026A1 (enExample)
TR (1) TR200000116T2 (enExample)
WO (1) WO1998053805A1 (enExample)
ZA (1) ZA984314B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
DE69912441T2 (de) 1998-08-19 2004-08-19 Skyepharma Canada Inc., Verdun Injizierbare wässerige propofoldispersionen
ES2232195T3 (es) * 1999-01-28 2005-05-16 Dinesh Shantilal Patel Solucion parenteral de propofol (2,6-diisopropilfenol) y 2,5-di-o-metil-1,4;3,6-dianhidro-d-glucitol como solvente.
US6177477B1 (en) * 1999-03-24 2001-01-23 American Home Products Corporation Propofol formulation containing TRIS
US6635456B2 (en) * 2001-02-09 2003-10-21 Fidia Farmaceutici S.P.A. Procedure for the preparation of pure phosphatides with phospholipase D
US6803046B2 (en) 2002-08-16 2004-10-12 Bracco International B.V. Sincalide formulations
KR100482269B1 (ko) * 2002-10-08 2005-04-14 센츄론(주) 2,6-디이소프로필페놀을 활성성분으로 하는 수용액상의마취용 주사제 및 그 제조방법
TR200502189T1 (tr) * 2002-12-09 2007-01-22 American Bioscience, Inc. Kompozisyonlar ve farmakolojik etken maddelerin aktarımı için yöntemler.
US20040225022A1 (en) * 2003-05-09 2004-11-11 Desai Neil P. Propofol formulation containing reduced oil and surfactants
US8476010B2 (en) 2003-07-10 2013-07-02 App Pharmaceuticals Llc Propofol formulations with non-reactive container closures
US8546453B2 (en) 2003-08-14 2013-10-01 Rensheng Zhang Propofol compositions and methods for reducing pain associated with propofol injection
JP2005154305A (ja) * 2003-11-21 2005-06-16 Showa Yakuhin Kako Kk ヒアルロン酸含有組成物の製造方法
CN100358513C (zh) * 2005-04-07 2008-01-02 常州市第四制药厂有限公司 一种丙泊酚注射液的制备工艺
KR101643416B1 (ko) 2005-08-31 2016-07-27 아브락시스 바이오사이언스, 엘엘씨 증가된 안정성을 가진 수 난용성 약물의 조성물 및 제조방법
LT1931321T (lt) 2005-08-31 2019-05-10 Abraxis Bioscience, Llc Kompozicijos, apimančios silpnai vandenyje tirpius farmacinius agentus ir antimikrobinius agentus
US9006280B2 (en) * 2008-11-20 2015-04-14 Teikoku Pharma Usa, Inc. Pyrazolone derivative formulations
US11110063B2 (en) 2017-08-25 2021-09-07 MAIA Pharmaceuticals, Inc. Storage stable sincalide formulations
EP3761961A4 (en) * 2018-03-07 2022-01-05 Andrew Xian Chen AQUEOUS FORMULATIONS FOR INSOLUBLE DRUGS
JP7135670B2 (ja) * 2018-09-27 2022-09-13 住友電気工業株式会社 光ファイバ及び紫外線硬化型樹脂組成物
JP7063217B2 (ja) * 2018-09-27 2022-05-09 住友電気工業株式会社 光ファイバの製造方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1089510B (de) 1959-03-23 1960-09-22 Rudolf Reiss Dr Verfahren zur Herstellung waessriger, injizierbarer Loesungen von 2-Methoxy-4-allylphenoxyessigsaeure-N, N-Diaethylamid
US4798846A (en) * 1974-03-28 1989-01-17 Imperial Chemical Industries Plc Pharmaceutical compositions
GB1472793A (en) * 1974-03-28 1977-05-04 Ici Ltd Pharmaceutical compositions
DE3221579A1 (de) 1982-06-08 1983-12-22 Eckert, Theodor, Prof. Dr., 4400 Münster Solubilisierung von in wasser schwerloeslichen wirkstoffen in waessrige loesung unter verwendung eines gemisches von cholinphosphorsaeureglycerindiester (cholin-lecithin) und natriumdesoxycholat als loesungsvermittler und die therapeutische verwendung der so erhaltenen waessrigen loesungen
CA1319886C (en) 1987-02-03 1993-07-06 Alberto Ferro Mixed micelle solutions
US5085864A (en) * 1989-10-30 1992-02-04 Abbott Laboratories Injectable formulation for lipophilic drugs
DE4039602A1 (de) * 1990-12-12 1992-06-17 Bauer Kurt Heinz Prof Dr Pharmazeutische formulierungen
GB9405593D0 (en) * 1994-03-22 1994-05-11 Zeneca Ltd Pharmaceutical compositions
ZA962214B (en) 1995-04-10 1996-10-07 Farmarc Nederland Bv Pharmaceutical composition
WO1997010814A1 (en) 1995-09-18 1997-03-27 Vesifact Ag Propofol nanodispersions
US5637625A (en) * 1996-03-19 1997-06-10 Research Triangle Pharmaceuticals Ltd. Propofol microdroplet formulations

Also Published As

Publication number Publication date
MY132911A (en) 2007-10-31
BR9809492A (pt) 2000-06-20
ZA984314B (en) 1998-12-08
AU735020B2 (en) 2001-06-28
AR012853A1 (es) 2000-11-22
KR20010013011A (ko) 2001-02-26
CN1268051A (zh) 2000-09-27
DZ2503A1 (fr) 2005-01-25
EP0991405B1 (en) 2003-01-15
IN187550B (enExample) 2002-05-18
HUP0002117A2 (hu) 2000-12-28
HUP0002117A3 (en) 2001-04-28
PL337026A1 (en) 2000-07-31
EP0991405A1 (en) 2000-04-12
JP2001527577A (ja) 2001-12-25
US6326406B1 (en) 2001-12-04
AU8209798A (en) 1998-12-30
DE69810771D1 (de) 2003-02-20
NO995831D0 (no) 1999-11-26
NO995831L (no) 2000-01-26
PA8451701A1 (es) 2000-05-24
TR200000116T2 (tr) 2000-05-22
CH692322A5 (it) 2002-05-15
WO1998053805A1 (en) 1998-12-03
CA2291261A1 (en) 1998-12-03
ATE230984T1 (de) 2003-02-15

Similar Documents

Publication Publication Date Title
PE75299A1 (es) Formulacion inyectable transparente de compuesto anestesico
BR9913433A (pt) Sistema desinfetante estabilizado composto de duas partes e composições e métodos a ele relacionado
CO5011119A1 (es) Jarabe antihistaminico estabilizado
NO964813D0 (no) Fremgangsmåte for stabilisering av duocarmycinderivater
CY1108070T1 (el) Παραγωγα κινολινονης, ως αναστολεις κινασης τυροσινης
NO973059L (no) Hydroksylaminderivater som er anvendbare for å öke den molekylære chaperonproduksjon, og fremstilling derav
ATE485815T1 (de) Zubereitungen zur perkutanen absorption
NO338966B1 (no) Nye porfyrinderivater, fortrinnsvis kloriner og/eller bakteriokloriner, fremgangsmåte for fremstilling derav, og anvendelse derav som antikreft, og/eller antiviralt og/eller antimikrobielt medikament i fotodynamisk terapi
ES2119804T5 (es) Composiciones transparentes de poliamidas con elevada estabilidad a los agentes quimicos.
SG114563A1 (en) Microbicidal and algicidal composition, microbicidal and algicidal process for a water system and process for producing a microbicidal and algicidal comosition
NO172674B (no) Fremgangsmaate for fremstilling av basiske, vandige preparater av karboksylsyrer
ES8704946A1 (es) Un procedimiento para la preparacion de triazolobenzodiazefinas.
PE26898A1 (es) Sales edulcorantes
MY114944A (en) Propanolamine derivatives, processes for their preparation pharmaceuticals comprising these compounds, and their use
PE20010111A1 (es) Derivado sustituido de pirazol
KR910004194A (ko) 안정한 주사용 수성 조성물 및 그러한 조성물의 안정화 방법
PA8534001A1 (es) Derivados de piperazina 1,4-disustituida utiles como bloqueadores alfa1,-adrenoceptores uro-selectivos
ES2056073T3 (es) Aril-aralquil-eteres, procedimientos para su preparacion y composicion farmaceutica que los comprende.
CO5021217A1 (es) Composiciones estables de mitoxantrona, procedimietno para prepararlas; utilizacion de dichas composiciones y medica- mentos que incluyen dichas soluciones para el tratamiento de enfermedades cancerosas
ES2153403T3 (es) Preparaciones farmaceuticas que contienen el factor citotoxico tumoral.
HUP9603489A2 (hu) Gyógyszerkészítmény és eljárás előállítására
BG106414A (en) Bioavailable dosage form of isotretinoin
ES2081783T1 (es) Alcaloides procedentes de mappia foetida, uso de estos y formulaciones que los contienen.
JPH075456B2 (ja) 点眼液
US5397784A (en) Stable parenteral compositions of vinblastine or vincristine

Legal Events

Date Code Title Description
FD Application declared void or lapsed